Human study PLS-00189

Serum Thymosin β4 Concentrations in Obstructive Sleep Apnea Syndrome Patients.

Cross-sectional study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

Serum Thymosin β4 Concentrations in Obstructive Sleep Apnea Syndrome Patients.primary · Journal of clinical laboratory analysis · 2016-04-18 · PMID 27086675 · DOI

Design and participants

Design: Cross-sectional study
Population: Patients with obstructive sleep apnea syndrome (158) and healthy subjects (94)
Conditions: Obstructive sleep apnea syndrome
Planned enrollment (registry): Not reported
Enrolled: Not reported
Randomized: Not reported
Completed follow-up: Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

What the authors reported

As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

Adverse events

None reported. That is not evidence of safety, and how safety was monitored isn’t described.

The authors concluded (paraphrased): Authors concluded that serum thymosin β4 concentrations were correlated with both the occurrence and the severity of obstructive sleep apnea syndrome.

Peptide Library’s assessment

An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

Limitations

inappropriate endpoint: Thymosin β4 was measured only as an endogenous serum biomarker. It was never administered, so the study says nothing about treatment effects.
confounding: Cross-sectional associations between serum levels and OSAS may be confounded. Only multivariable adjustment is described in the abstract.
abstract only: Only the abstract is available in the record. Full methods, effect estimates and funding are not reported.
other: No thymosin β4 was administered; the study measured endogenous serum levels as a biomarker, so it gives no evidence on the compound's effects or safety.

No risk-of-bias assessment has been published for this study’s results.

Claims this study informs

Improves dry eye signs and symptoms: not eligible (not primary study) for “Ocular discomfort and corneal staining”
Is safe for human administration: not eligible (not primary study) for “Adverse events, serious adverse events and discontinuations”

Where each value comes from

author_conclusion: PMID 27086675, abstract (Conclusions, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
design: PMID 27086675, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
participants: PMID 27086675, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
population: PMID 27086675, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).